aim
undertook
studi
defin
incid
toxigen
clostridium
difficil
hospit
characteris
isol
method
unform
stool
test
presenc
toxin
tcda
toxin
b
tcdb
cultur
c
difficil
cultur
filtrat
also
test
tcda
tcdb
detect
tcda
tcdb
gene
carri
b
strain
polymeras
chain
reaction
pcr
minimum
inhibitori
concentr
mic
metronidazol
vancomycin
clindamycin
isol
test
use
etest
pcr
ribotyp
carri
isol
result
incid
clostridium
difficil
associ
diseas
cdad
case
per
admiss
discharg
case
per
patient
day
case
occur
renal
haematolog
patient
cdad
common
patient
age
year
male
gender
indian
popul
underrepres
fourteen
isol
b
strain
suscept
metronidazol
one
strain
show
intermedi
resist
vancomycin
isol
suscept
clindamycin
thirtyf
isol
pcr
ribotyp
clindamycin
mic
mgl
thirtythre
pcr
ribotyp
b
one
clindamycin
mic
mgl
b
strain
pcr
ribotyp
c
rang
mic
clindamycin
mgl
conclus
incid
cdad
hospit
rel
low
isol
remain
suscept
metronidazol
vancomycin
clostridium
difficil
anaerob
pathogen
import
caus
nosocomi
diarrhoea
produc
two
exotoxin
contribut
pathogenesi
toxin
tcda
potent
enterotoxin
thought
caus
clinic
symptom
due
induc
fluid
secret
mucos
damag
toxin
b
tcdb
approxim
time
cytotox
toxin
effect
tcdb
thought
depend
initi
tissu
damag
tcda
suggest
toxin
work
synergist
clostridium
difficil
associ
diseas
cdad
well
describ
north
america
europ
littl
data
preval
cdad
southeast
asia
kumarasingh
et
al
report
preval
bacteri
agent
diarrhoeal
diseas
month
period
anoth
larg
singapor
hospit
studi
c
difficil
isol
case
test
howev
c
difficil
sought
request
toxin
test
perform
c
difficil
isol
sensit
metronidazol
undertook
studi
defin
incid
toxigen
c
difficil
hospit
characteris
isol
singapor
gener
hospit
sgh
bed
tertiari
referr
hospit
unform
stool
sgh
inpati
sent
depart
patholog
octob
februari
test
presenc
tcda
tcdb
use
premier
toxin
b
enzym
immunoassay
eia
kit
meridian
diagnost
usa
follow
manufactur
instruct
overview
specimen
flow
given
fig
stool
inocul
onto
c
difficil
select
agar
cdc
anaerob
agar
becton
dickinson
usa
posit
cultur
identifi
microscopi
coloni
appear
yellowgreen
fluoresc
long
wave
uv
light
characterist
smell
neg
reaction
lecithinas
lipas
egg
yolk
agar
franc
test
tcda
tcdb
direct
stool
ceas
februari
sever
acut
respiratori
syndrom
sar
outbreak
singapor
howev
cultur
c
difficil
continu
total
toxigen
isol
reach
overnight
growth
cdc
anaerob
plate
harvest
ml
loop
resuspend
ml
instagen
matrix
biorad
usa
boil
min
suspens
centrifug
g
min
supernat
remov
store
strain
cultur
peptoneyeast
extractglucos
broth
anaerob
condit
h
cultur
centrifug
g
min
supernat
remov
filter
mm
filter
membran
bijou
bottl
cultur
filtrat
ml
ad
ml
diluent
perform
use
premier
toxin
b
enzym
immunoassay
eia
kit
meridian
diagnost
follow
manufactur
instruct
carri
use
premier
toxin
enzym
immunoassay
eia
kit
meridian
diagnost
follow
manufactur
instruct
tcdb
assay
cultur
filtrat
c
difficil
toxb
cytotox
assay
techlab
usa
use
confirm
product
toxin
b
phosphat
buffer
salin
antitoxin
ad
pair
well
microtitr
plate
contain
monolay
hela
cell
fifti
ml
cultur
filtrat
appropri
control
ad
pair
well
duplic
microtitr
plate
incub
co
h
invert
microscop
use
observ
round
cell
necessari
plate
incub
h
done
b
strain
use
method
describ
kato
et
al
minimum
inhibitori
concentr
mic
mic
metronidazol
vancomycin
clindamycin
isol
test
use
etest
ab
biodisk
sweden
brucella
agar
sheep
blood
haemin
vitamin
k
becton
dickinson
test
mic
clindamycin
even
though
inappropri
therapi
cdad
resist
antimicrobi
surrog
strain
marker
data
enter
analys
whonet
pcr
ribotyp
carri
isol
use
method
describ
stubb
et
al
octob
februari
stool
sampl
receiv
stool
posit
tcda
tcdb
eia
second
look
cultur
addit
stool
grew
c
difficil
whose
cultur
filtrat
tcda
tcdb
posit
eia
overal
unabl
isol
c
difficil
stool
toxin
posit
eia
direct
test
combin
number
toxigen
strain
cultur
negativedirect
toxin
posit
specimen
incid
cdad
case
per
admiss
discharg
case
per
patient
day
breakdown
case
specialti
shown
tabl
breakdown
case
age
group
shown
tabl
breakdown
case
ethnic
origin
sex
shown
tabl
respect
fourteen
isol
neg
tcda
posit
tcdb
b
strain
smaller
pcr
product
bp
tcda
keep
phenotyp
isol
suscept
metronidazol
one
strain
show
intermedi
resist
vancomycin
strain
suscept
clindamycin
sixtythre
percent
isol
fulli
resist
clindamycin
tabl
select
repres
pcr
ribotyp
shown
fig
thirtyf
isol
pcr
ribotyp
clindamycin
mic
mgl
thirtythre
pcr
ribotyp
b
one
clindamycin
mic
mgl
b
isol
pcr
ribotyp
c
rang
mic
clindamycin
mgl
seven
pcr
ribotyp
repres
isol
remain
isol
uniqu
pcr
ribotyp
gener
impress
singapor
c
difficil
caus
degre
morbid
mortal
local
compar
hospit
popul
western
countri
perceiv
low
rate
sever
diseas
death
may
led
underestim
import
cdad
recent
outbreak
quebec
hospit
experienc
case
cdad
per
admiss
although
decreas
per
admiss
infect
control
measur
implement
absenc
outbreak
incid
may
low
exampl
pari
hospit
annual
incid
vari
per
admiss
unit
state
report
incid
four
hospit
vari
per
admissiondischarg
outbreak
seven
per
discharg
absenc
outbreak
epidem
larg
caus
clindamycinresist
strain
us
hospit
discharg
cdad
list
diagnosi
doubl
per
popul
per
overal
rate
severalfold
higher
person
year
age
case
per
age
group
next
highest
rate
year
case
per
hospit
data
similar
sweden
incid
cdad
countrywid
survey
vari
case
per
admiss
howev
incid
term
bedday
differ
per
bed
day
sweden
compar
per
bed
day
singapor
anoth
swedish
studi
rebro
counti
incid
similar
vari
per
admiss
high
incid
ward
geriatr
case
per
admiss
infecti
diseas
case
per
admiss
nephrolog
case
per
admiss
later
studi
swedish
teach
hospit
slightli
higher
incid
case
per
admiss
like
studi
higher
incid
nephrolog
case
per
admiss
haematolog
case
per
admiss
ward
like
reflect
antimicrobi
chemotherapeut
drug
use
specialti
contrast
studi
three
common
pcr
ribotyp
compris
hospit
associ
case
versu
singapor
indic
due
endogen
strain
rather
hospit
spread
quit
difficult
draw
comparison
incid
cdad
paper
differ
countri
often
compar
differ
measur
hospit
popul
howev
appear
incid
singapor
lower
end
spectrum
although
affect
age
group
ward
popul
risk
similar
cdad
studi
occur
male
fourfold
differ
incid
patient
repres
three
major
ethnic
group
singapor
howev
confid
interv
latter
wide
overlap
studi
design
exclud
confound
factor
like
underli
ill
princip
diagnosi
differ
subpopul
laboratori
detect
cdad
base
toxin
assay
perform
toxin
assay
c
difficil
isol
neg
direct
toxin
assay
stool
secondlook
shown
detect
extra
toxinproduc
strain
would
gone
undetect
otherwis
studi
direct
toxin
detect
stool
would
detect
toxigen
isol
almost
ident
result
obtain
et
al
like
also
use
hela
cell
consid
slightli
less
sensit
vero
cell
may
partli
explain
low
sensit
reason
cultur
perform
link
cost
technic
difficulti
howev
et
al
estim
total
cost
includ
labour
agar
reagent
toxin
detect
coloni
exceed
euro
au
laboratori
cultur
problem
larg
dedic
anaerob
section
virolog
section
provid
cell
cultur
howev
resourc
may
readili
avail
laboratori
disadvantag
much
longer
turnaround
time
cultur
least
day
compar
direct
toxin
assay
sever
minut
trade
sensit
timeli
result
need
evalu
laboratori
sometim
speed
toxin
assay
negat
batch
specimen
studi
may
need
perform
compar
cultur
filtrat
secondlook
toxin
assay
versu
repeat
direct
toxin
assay
repeat
specimen
note
cultur
way
type
strain
test
antimicrobi
suscept
clinic
isol
patient
cdad
usual
produc
tcda
tcd
b
increas
number
infect
due
b
strain
clostridium
difficil
b
strain
appar
clonal
origin
wide
distribut
north
america
europ
studi
b
isol
canada
unit
state
poland
unit
kingdom
franc
japan
netherland
pcr
ribotyp
belong
serogroup
f
major
isol
show
resist
clindamycin
anoth
intern
studi
b
strain
unit
kingdom
belgium
unit
state
strain
kb
truncat
tcda
gene
characterist
toxinotyp
viii
strain
twenti
pcr
ribotyp
preval
b
strain
report
initi
low
lyerli
found
two
strain
collect
toxigen
c
difficil
isol
multicentr
trial
unit
state
unit
kingdom
strain
sent
refer
centr
type
b
franc
b
strain
compris
toxigen
c
difficil
isol
kb
delet
pcr
ribotyp
howev
recent
paper
poland
report
toxigen
c
difficil
strain
isol
b
clonal
indistinguish
japanes
control
strain
random
amplif
polymorph
dna
rapd
pcr
ribotyp
delet
tcda
high
level
resist
clindamycin
backdrop
preval
b
isol
studi
rel
high
even
though
b
isol
pcr
ribotyp
clindamycin
mic
variabl
rang
mgl
routin
antimicrobi
suscept
test
c
difficil
carri
resist
rare
laboratori
cultur
organ
howev
increas
number
report
resist
studi
franc
two
time
period
decreas
suscept
metronidazol
six
strain
mgl
minim
inhibitori
concentr
isol
metronidazol
remain
static
mgl
wherea
minim
inhibitori
concentr
isol
decreas
mgl
mgl
vancomycin
remain
static
mgl
mgl
respect
recommend
period
studi
conduct
detect
emerg
resist
strain
studi
sweden
c
difficil
isol
collect
year
suscept
metronidazol
vancomycin
wherea
intermedi
fulli
resist
clindamycin
unlik
studi
particular
ribotyp
associ
clindamycin
resist
howev
anoth
part
sweden
isol
resist
clindamycin
belong
fingerprint
group
suggest
clonal
spread
clone
clindamycinresist
c
difficil
also
associ
larg
outbreak
unit
state
recent
pelaez
report
spain
overal
rate
resist
metronidazol
although
full
resist
vancomycin
observ
overal
rate
intermedi
resist
metronidazol
vancomycin
retain
good
activ
isol
although
one
isol
show
reduc
suscept
vancomycin
littl
surpris
standard
therapi
cdad
hospit
metronidazol
oral
vancomycin
hardli
use
compar
studi
high
proport
isol
resist
clindamycin
conclus
incid
cdad
hospit
rel
low
must
emphasis
like
underestim
patient
diagnos
stool
specimen
submit
laboratori
isol
remain
suscept
recommend
antimicrobi
metronidazol
vancomycin
eia
use
diagnosi
cdad
popul
abl
detect
tcdb
preval
b
isol
rel
high
continu
surveil
carri
preempt
introduct
potenti
virul
strain
c
difficil
